Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1983 1
1985 1
1986 1
1988 1
1990 1
1992 1
1999 2
2000 1
2004 1
2005 1
2006 3
2007 1
2008 3
2009 1
2010 4
2011 1
2012 5
2013 1
2015 2
2016 2
2017 1
2018 2
2019 2
2020 2
Text availability
Article attribute
Article type
Publication date

Search Results

41 results
Results by year
Filters applied: . Clear all
Page 1
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators. Kappos L, et al. Lancet. 2018 Mar 31;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23. Lancet. 2018. PMID: 29576505 Clinical Trial.
At baseline, the mean time since first multiple sclerosis symptoms was 16·8 years (SD 8·3), and the mean time since conversion to SPMS was 3·8 years (SD 3·5); 1055 (64%) patients had not relapsed in the previous 2 years, and 918 (56%) of 1651 needed walking assistance. 903 (82%) …
At baseline, the mean time since first multiple sclerosis symptoms was 16·8 years (SD 8·3), and the mean time since conversion to SPMS was 3 …
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group. Green JB, et al. N Engl J Med. 2015 Jul 16;373(3):232-42. doi: 10.1056/NEJMoa1501352. Epub 2015 Jun 8. N Engl J Med. 2015. PMID: 26052984 Free article. Clinical Trial.
Sitagliptin was noninferior to placebo for the primary composite cardiovascular outcome (hazard ratio, 0.98; 95% CI, 0.88 to 1.09; P<0.001). Rates of hospitalization for heart failure did not differ between the two groups (hazard ratio, 1.00; 95% CI, 0.83 to 1.20; P
Sitagliptin was noninferior to placebo for the primary composite cardiovascular outcome (hazard ratio, 0.98; 95% CI, 0.88 to 1.09; P& …
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
Hernandez AF, Green JB, Janmohamed S, D'Agostino RB Sr, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM, McMurray JJV, Del Prato S; Harmony Outcomes committees and investigators. Hernandez AF, et al. Lancet. 2018 Oct 27;392(10157):1519-1529. doi: 10.1016/S0140-6736(18)32261-X. Epub 2018 Oct 2. Lancet. 2018. PMID: 30291013 Clinical Trial.
The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 9 …
The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albigluti …
Basal insulin and cardiovascular and other outcomes in dysglycemia.
ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. ORIGIN Trial Investigators, et al. N Engl J Med. 2012 Jul 26;367(4):319-28. doi: 10.1056/NEJMoa1203858. Epub 2012 Jun 11. N Engl J Med. 2012. PMID: 22686416 Free article. Clinical Trial.
Rates of incident cardiovascular outcomes were similar in the insulin-glargine and standard-care groups: 2.94 and 2.85 per 100 person-years, respectively, for the first coprimary outcome (hazard ratio, 1.02; 95% confidence interval [CI], 0.94 to 1.11; P=0.63) and 5.52 and …
Rates of incident cardiovascular outcomes were similar in the insulin-glargine and standard-care groups: 2.94 and 2.85 per 100 person-years, …
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.
ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. ORIGIN Trial Investigators, et al. N Engl J Med. 2012 Jul 26;367(4):309-18. doi: 10.1056/NEJMoa1203859. Epub 2012 Jun 11. N Engl J Med. 2012. PMID: 22686415 Free article. Clinical Trial.
The use of n-3 fatty acids also had no significant effect on the rates of major vascular events (1034 patients [16.5%] vs. 1017 patients [16.3%]; hazard ratio, 1.01; 95% CI, 0.93 to 1.10; P=0.81), death from any cause (951 [15.1%] vs. 964 [15.4%]; hazard ratio, 0.98; 95% C …
The use of n-3 fatty acids also had no significant effect on the rates of major vascular events (1034 patients [16.5%] vs. 1017 patients [16 …
Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators. Parving HH, et al. N Engl J Med. 2012 Dec 6;367(23):2204-13. doi: 10.1056/NEJMoa1208799. Epub 2012 Nov 3. N Engl J Med. 2012. PMID: 23121378 Free article. Clinical Trial.
After a median follow-up of 32.9 months, the primary end point had occurred in 783 patients (18.3%) assigned to aliskiren as compared with 732 (17.1%) assigned to placebo (hazard ratio, 1.08; 95% confidence interval [CI], 0.98 to 1.20; P=0.12). ...The proportion of patient …
After a median follow-up of 32.9 months, the primary end point had occurred in 783 patients (18.3%) assigned to aliskiren as compared with 7 …
Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS.
Cornel JH, Bakris GL, Stevens SR, Alvarsson M, Bax WA, Chuang LM, Engel SS, Lopes RD, McGuire DK, Riefflin A, Rodbard HW, Sinay I, Tankova T, Wainstein J, Peterson ED, Holman RR; TECOS Study Group. Cornel JH, et al. Diabetes Care. 2016 Dec;39(12):2304-2310. doi: 10.2337/dc16-1415. Epub 2016 Oct 14. Diabetes Care. 2016. PMID: 27742728 Clinical Trial.
Sitagliptin therapy was not associated with cardiovascular outcomes for any eGFR stage (interaction P values were all >0.44). ...
Sitagliptin therapy was not associated with cardiovascular outcomes for any eGFR stage (interaction P values were all >0.44). ...
Conformations of the iduronate ring in short heparin fragments described by time-averaged distance restrained molecular dynamics.
Muñoz-García JC, Corzana F, de Paz JL, Angulo J, Nieto PM. Muñoz-García JC, et al. Glycobiology. 2013 Nov;23(11):1220-9. doi: 10.1093/glycob/cwt058. Epub 2013 Jul 31. Glycobiology. 2013. PMID: 23903025
The polyconformational behavior of L-iduronic acid (L-IdoA2S) in heparin derivatives has been previously analyzed in terms of intra-ring proton-proton vicinal coupling constants ((3)JHH) through mathematical fit of experimental and theoretical values (Ferro DR, Provasoli A, Ragaz …
The polyconformational behavior of L-iduronic acid (L-IdoA2S) in heparin derivatives has been previously analyzed in terms of intra-ring pro …
Access and unmet needs to multiple sclerosis care in a cohort of Argentinean patients.
Carnero Contentti E, Pettinicchi JP, López PA, Alonso R, Garcea O, Balbuena ME, Bortoluzzi C, Silva E, Cabrera M, Curbelo MC, Hryb JP, Di Pace JL, Perassolo M, Ianardi S, Mainella C, Mellinger S, Migliacci L, Pagani Cassara F, Sinay V, Carra A, Qüesta Laudani M, Ruiz Romagnoli E, Liwacki S, Piedrabuena R, Tizio S, Tkachuk V. Carnero Contentti E, et al. Mult Scler Relat Disord. 2019 Aug;33:88-93. doi: 10.1016/j.msard.2019.05.024. Epub 2019 May 30. Mult Scler Relat Disord. 2019. PMID: 31174044
PHI was independently associated with appropriate delivery of MS medication (OR = 0.81, p = 0.01). CONCLUSION: This study showed that MS patients had access barriers to receive MS medication properly, especially those with SRHI (public sector)....
PHI was independently associated with appropriate delivery of MS medication (OR = 0.81, p = 0.01). CONCLUSION: This study showed that …
The relationship between alexithymia, empathy and moral judgment in patients with multiple sclerosis.
Gleichgerrcht E, Tomashitis B, Sinay V. Gleichgerrcht E, et al. Eur J Neurol. 2015 Sep;22(9):1295-303. doi: 10.1111/ene.12745. Epub 2015 Jun 11. Eur J Neurol. 2015. PMID: 26095629

RESULTS: Relative to controls, patients exhibited decreased levels of other-oriented empathy [empathic concern (P < 0.01) and fantasy (P < 0.01)], increased levels of self-oriented personal distress (P < 0.01), as well as higher rates of alexithymia

RESULTS: Relative to controls, patients exhibited decreased levels of other-oriented empathy [empathic concern (P < 0.01) and fant

41 results
Jump to page
Feedback